Stock analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Alliance Global Partners increased their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.
Read Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Stock Performance
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last released its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. As a group, analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 260.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 82.26% of the stock is owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
- Five stocks we like better than Tonix Pharmaceuticals
- Following Congress Stock Trades
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- NYSE Stocks Give Investors a Variety of Quality Options
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What is a Dividend King?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.